4.7 Review

Membranous nephropathy: Systems biology-based novel mechanism and traditional Chinese medicine therapy

期刊

FRONTIERS IN PHARMACOLOGY
卷 13, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.969930

关键词

membranous nephropathy; anti-PLA 2 R antibody; gut microbiota; long non-coding RNAs; metabolite biomarkers; traditional Chinese medicine

资金

  1. National Key Research and Development Project
  2. National Natural Science Foundation of China
  3. Shaanxi Science and Technology Innovation Team
  4. [2019YFC1709405]
  5. [82074002]
  6. [81872985]
  7. [2019TD-016]

向作者/读者索取更多资源

Membranous nephropathy (MN) is an autoimmune disease that affects the glomerulus. Research has shown progress in understanding the causes and mechanisms of MN. Various antibodies have been identified, but there are still many unresolved questions. This review summarizes the current evidence and explores the applications of traditional Chinese medicines in MN treatment. It also discusses the challenges and future directions in understanding MN.
Membranous nephropathy (MN) is a renal-limited non-inflammatory autoimmune disease in the glomerulus, which is the second or third main cause of end-stage kidney diseases in patients with primary glomerulonephritis. Substantial achievements have increased our understanding of the aetiology and pathogenesis of murine and human MN. The identification of nephritogenic autoantibodies against neutral endopeptidase, phospholipase A(2) receptor (PLA(2)R) and thrombospondin type-1 domain-containing 7A (THSD7A) antigens provide more specific concept-driven intervention strategies for treatments by specific B cell-targeting monoclonal antibodies to inhibit antibody production and antibody-antigen immune complex deposition. Furthermore, additional antibody specificities for antigens have been discovered, but their pathogenic effects are uncertain. Although anti-PLA(2)R and anti-THSD7A antibodies as a diagnostic marker is widely used in MN patients, many questions including autoimmune response development, antigenic epitopes, and podocyte damage signalling pathways remain unresolved. This review describes the current available evidence regarding both established and novel molecular mechanisms based on systems biology approaches (gut microbiota, long non-coding RNAs, metabolite biomarkers and DNA methylation) in MN, with an emphasis on clinical findings. This review further summarizes the applications of traditional Chinese medicines such as Tripterygium wilfordii and Astragalus membranaceus for MN treatment. Lastly, this review considers how the identification of novel antibodies/antigens and unresolved questions and future challenges reveal the pathogenesis of MN.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据